Establishment of Two Dimensional (2D) and Three-Dimensional (3D) Melanoma Primary Cultures as a Tool for In Vitro Drug Resistance Studies

Rodríguez, Nataly Cruz; Lineros, Johanna; Rodríguez, Carol Stefany; Martínez, Lina; Rodríguez, Josefa Antonia

doi:10.1007/978-1-4939-8979-9_8

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two‐dimensional models, defined as melanoma cells cultured in a monolayer, are technically simple and widely used for screening potential treatments as well as characterization of the proliferation and migration capability of human and murine melanoma cells (Cruz Rodriguez et al, 2019). To measure proliferation in 2D systems, several assays are available including live proliferation measurement, live cell imaging, detection of metabolic activity (e.g., MTT and XTT), labeling of antigens (e.g., Ki67), and labeling of DNA (e.g., bromodeoxyuridine (BrdU)) followed by fluorescence detection (Erdmann et al, 2019; Lanigan et al, 2020; Mastroianni et al, 2019).…”

Section: In Vitro Model Systemsmentioning

confidence: 99%

Advancements in melanoma cancer metastasis models

Melo

Kumar

Riess

et al. 2023

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Metastatic melanoma is a complex and deadly disease. Due to its complexity, the development of novel therapeutic strategies to inhibit metastatic melanoma remains an outstanding challenge. Our ability to study metastasis is advanced with the development of in vitro and in vivo models that better mimic the different steps of the metastatic cascade beginning from primary tumor initiation to final metastatic seeding. In this review, we provide a comprehensive summary of in vitro models, in vivo models, and in silico platforms to study the individual steps of melanoma metastasis. Furthermore, we highlight the advantages and limitations of each model and discuss the challenges of how to improve current models to enhance translation for melanoma cancer patients and future therapies.

show abstract

Section: In Vitro Model Systemsmentioning

confidence: 99%

Advancements in melanoma cancer metastasis models

Melo

Kumar

Riess

et al. 2023

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…To evaluate the efficacy of new compounds or study melanoma pathophysiology, several tests can be carried out on 3D spheroid models, such as MTT/MTS assay, measurement of spheroids area, apoptotic and live/dead viability assays, as well as the study of tumor metabolism, progression, invasion, and drug resistance [74,[132][133][134][135]. Various reports have addressed the differences between results obtained using 2D and 3D spheroids models.…”

Section: Spheroid Modelmentioning

confidence: 99%

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Matias

Pinho

Penetra

et al. 2021

Cells

View full text Add to dashboard Cite

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and resistance to currently used treatments. To overcome the limitations of the available therapeutic options, the discovery and development of new, more effective, and safer therapies is required. In this review, the different research steps involved in the process of antimelanoma drug evaluation and selection are explored, including information regarding in silico, in vitro, and in vivo experiments, as well as clinical trial phases. Details are given about the most used cell lines and assays to perform both two- and three-dimensional in vitro screening of drug candidates towards melanoma. For in vivo studies, murine models are, undoubtedly, the most widely used for assessing the therapeutic potential of new compounds and to study the underlying mechanisms of action. Here, the main melanoma murine models are described as well as other animal species. A section is dedicated to ongoing clinical studies, demonstrating the wide interest and successful efforts devoted to melanoma therapy, in particular at advanced stages of the disease, and a final section includes some considerations regarding approval for marketing by regulatory agencies. Overall, considerable commitment is being directed to the continuous development of optimized experimental models, important for the understanding of melanoma biology and for the evaluation and validation of novel therapeutic strategies.

show abstract

“…Furthermore, mutations in the p16/CDKN2 tumor suppressor gene have been revealed in different melanoma cell lines during 2D culture, but not in primary lesions in situ [53,54]. In addition, despite chemotherapeutic drugs or radiation therapy demonstrate efficacy in 2D cultures, their activity may change significantly in vivo, partially affected by the TME [55,56].…”

Section: Recent Development In Human 3d Melanoma Modelsmentioning

confidence: 99%

Recent developments of 3D models of the tumor microenvironment for cutaneous melanoma: Bridging the gap between the bench and the bedside?

Hölken¹,

Teusch²

2021

J Transl Sci

View full text Add to dashboard Cite

In cancer drug discovery, 3D approaches have been implemented over the last years to model the complex tumor architecture and the heterogenous components of the tumor microenvironment. Cutaneous melanoma represents a cancer of substantial unmet need with steadily growing incidence. Bioengineering techniques are increasingly applied to design melanoma-specific models. Here, we summarize how extracellular and cellular elements of the melanoma tumor microenvironment have been studied in 3D cell culture models. We review the benefits of such models and address their limitations and future perspectives for the development of novel therapeutic strategies.

show abstract

Establishment of Two Dimensional (2D) and Three-Dimensional (3D) Melanoma Primary Cultures as a Tool for In Vitro Drug Resistance Studies

Cited by 9 publications

References 17 publications

Advancements in melanoma cancer metastasis models

Advancements in melanoma cancer metastasis models

The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval

Recent developments of 3D models of the tumor microenvironment for cutaneous melanoma: Bridging the gap between the bench and the bedside?

Contact Info

Product

Resources

About